A2M Knockout cell line (Hep G2)

Gene knockout cell lines are generated using CRISPR-Cas9 based technology to precisely disrupt target genes, enabling functional genomics research, disease modeling, and target validation.

A2M (alpha-2-macroglobulin) encodes a broad-spectrum protease inhibitor and cytokine transporter that uses a bait-and-trap mechanism to inhibit proteases such as trypsin, thrombin, and collagenase. It can also bind and inhibit inflammatory cytokines, thereby modulating inflammatory signaling. A2M additionally participates in clearance and degradation of beta-amyloid, supporting roles in extracellular protease regulation, cytokine homeostasis, and protein clearance.

A human liver tumor cell line established from the tumor tissue of a 15-year-old Caucasian male in 1975, originally described as a well-differentiated hepatocellular carcinoma and later reclassified by some sources as a hepatoblastoma. The cells produce multiple plasma proteins, including albumin, alpha-fetoprotein, alpha2-macroglobulin, alpha1-antitrypsin, transferrin, and plasminogen. Hepatitis B virus surface antigens have not been detected, and the cells respond to stimulation with human growth hormone.

Before delivery, each clone is authenticated by STR, tested for sterility and mycoplasma, and genotype‑verified by two‑round PCR‑sequencing. Comprehensive QC data accompany every shipment to support reproducible research.